The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms
Abstract
Purpose: TP53 mutations are highly prevalent in head and neck squamous cell carcinoma (HNSCC) and associated with increased resistance to conventional treatment primarily consisting of chemotherapy and radiation. Restoration of wild-type p53 function in TP53-mutant cancer cells represents an attractive therapeutic approach and has been explored in recent years. In this study, the efficacy of a putative p53 reactivator called COTI-2 was evaluated in HNSCC cell lines with different TP53 status. Experimental Design: Clonogenic survival assays and an orthotopic mouse model of oral cancer were used to examine in vitro and in vivo sensitivity of HNSCC cell lines with either wild-type, null, or mutant TP53 to COTI-2 alone, and in combination with cisplatin and/or radiation. Western blotting, cell cycle, live-cell imaging, RNA sequencing, reverse-phase protein array, chromatin immunoprecipitation, and apoptosis analyses were performed to dissect molecular mechanisms. Results: COTI-2 decreased clonogenic survival of HNSCC cells and potentiated response to cisplatin and/or radiation in vitro and in vivo irrespective of TP53 status. Mechanistically, COTI-2 normalized wild-type p53 target gene expression and restored DNA-binding properties to the p53-mutant protein in HNSCC. In addition, COTI-2 induced DNA damage and replication stress responses leading to apoptosis and/or senescence. Furthermore, COTI-2 lead to activation of AMPK and inhibition of the mTOR pathways in vitro in HNSCC cells. Conclusions: COTI-2 inhibits tumor growth in vitro and in vivo in HNSCC likely through p53-dependent and p53-independent mechanisms. Combination of COTI-2 with cisplatin or radiation may be highly relevant in treating patients with HNSCC harboring TP53 mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“COTI-2 has been shown to suppress tumor growth by inducing apoptosis and cell cycle arrest in both p53-dependent and p53-independent manners.356,358”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [356]
In the citing paper
“COTI-2 was reported to restore DNA-binding properties to the p53-mutant protein,449,451–453”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [449]
In the citing paper
“COTI-2 inhibits tumor growth in a p53-dependent and p53-independent manner, ultimately leading to cell cycle arrest and apoptosis.448–450”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [449]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Research works printed but not linked: 28
- Adelstein, 2003, An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer, J Clin Oncol, 21, 92, 10.1200/JCO.2003.01.008 · DOI · Paper page
- Agrawal, 2011, Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1, Science, 333, 1154, 10.1126/science.1206923 · DOI · Paper page
- Pickering, 2013, Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers, Cancer Discov, 3, 770, 10.1158/2159-8290.CD-12-0537 · DOI · Paper page
- Cancer Genome Atlas Network, 2015, Comprehensive genomic characterization of head and neck squamous cell carcinomas, Nature, 517, 576, 10.1038/nature14129 · DOI · Paper page
- Rivlin, 2015, p53 orchestrates between normal differentiation and cancer, Semin Cancer Biol, 32, 10, 10.1016/j.semcancer.2013.12.006 · DOI
- Osman, 2015, Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients, Cancer Res, 75, 1205, 10.1158/0008-5472.CAN-14-2729 · DOI
- Bykov, 2005, Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs, J Biol Chem, 280, 30384, 10.1074/jbc.M501664200 · DOI · Paper page
- Yu, 2012, Allele-specific p53 mutant reactivation, Cancer Cell, 21, 614, 10.1016/j.ccr.2012.03.042 · DOI · Paper page
- Yu, 2014, Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism, Oncotarget, 5, 8879, 10.18632/oncotarget.2432 · DOI · Paper page
- Salim, 2016, COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo, Oncotarget, 7, 41363, 10.18632/oncotarget.9133 · DOI · Paper page
- Maleki, 2018, Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines, PLoS One, 13, e0191766, 10.1371/journal.pone.0191766 · DOI
- Westin, 2018, Safety and early efficacy signals for COTI-2, an orally available small molecule targeting p53, in a phase I trial of recurrent gynecologic cancer [abstract], 10.1158/1538-7445.AM2018-CT033 · doi:10.1158/1538-7445.am2018-ct033
- Osman, 2015, Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence, Mol Cancer Ther, 14, 608, 10.1158/1535-7163.MCT-14-0735-T · DOI
- Chou, 2006, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Pharmacol Rev, 58, 621, 10.1124/pr.58.3.10 · DOI · Paper page
- Tanaka, 2017, Synergistic antitumor activity of HDAC inhibitor vorinostat combined with WEE1 inhibitor AZD1775 in head and neck squamous cell carcinoma harboring high-risk TP53 mutation, Clin Cancer Res, 23, 6541, 10.1158/1078-0432.CCR-17-0947 · DOI
- Tanaka, 2018, Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1, Oncogene, 37, 1279, 10.1038/s41388-017-0032-z · DOI
- Tanaka, 2018, Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity, Oral Oncol, 87, 49, 10.1016/j.oraloncology.2018.10.018 · DOI
- Skinner, 2012, TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence, Clin Cancer Res, 18, 290, 10.1158/1078-0432.CCR-11-2260 · DOI · Paper page
- Chang, 2014, A comprehensive and high resolution genome-wide response of p53 to stress, Cell Rep, 8, 514, 10.1016/j.celrep.2014.06.030 · DOI
- Dohn, 2001, p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes, Oncogene, 20, 3193, 10.1038/sj.onc.1204427 · DOI · Paper page
- Byers, 2012, Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1, Cancer Discov, 2, 798, 10.1158/2159-8290.CD-12-0112 · DOI · Paper page
- Ribeiro-Rodrigues, 2017, Role of connexin 43 in different forms of intercellular communication–gap junctions, extracellular vesicles and tunnelling nanotubes, J Cell Sci, 130, 3619, 10.1242/jcs.200667 · DOI · Paper page
- El-Fouly, 1987, Scrape-loading and dye transfer, a rapid and simple technique to study gap junctional intracellular communication, Expt Cell Res, 168, 422, 10.1016/0014-4827(87)90014-0 · DOI · Paper page
- Babica, 2016, Scrape loading/dye transfer assay, Methods Mol Biol, 1437, 133, 10.1007/978-1-4939-3664-9_9 · doi:10.1007/978-1-4939-3664-9_9
- Azzam, 2001, Direct evidence for the participation of gap junction mediated intercellular communication in the transmission of damage signals from a-particle irradiated to nonirradiated cells, PNAS, 98, 473
- Lindemann, 2018, Targeting the DNA damage response in OSCC with TP53 mutations, J Dent Res, 97, 635, 10.1177/0022034518759068 · DOI · Paper page
- Fitzgerald, 2015, Reactive oxygen species and p21Waf1/Cip1 are both essential for p52-mediated senescence of head and neck cancer cells, Cell Death Dis, 6, e1678, 10.1038/cddis.2015.44 · DOI
- Jeon, 2016, Regulation and function of AMPK in physiology and diseases, Exp Mol Med, 48, e245, 10.1038/emm.2016.81 · DOI · Paper page
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Targeting p53 for the treatment of cancer
Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 349
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Qian, Y., Gong, Y., Fan, Z., Luo, G., Huang, Q., Deng, S., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00958-3 · Cited by 312
Small-molecule correctors and stabilizers to target p53
Fallatah, M. M. J., Law, F. V., Chow, W. A., & Kaiser, P. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.007 · Cited by 44
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Lindemann, A., Patel, A. A., Silver, N. L., Tang, L., Liu, Z., Wang, L., Tanaka, N., Rao, X., Takahashi, H., Maduka, N. K., Zhao, M., Chen, T.-C., Liu, W., Gao, M., Wang, J., Frank, S. J., Hittelman, W. N., Mills, G. B., Myers, J. N., & Osman, A. A.
- Venue
- Clinical Cancer Research
- Published
- 2019-09-13
- Volume
- 25
- Issue
- 18
- Pages
- 5650-5662
- ISSN
- 1078-0432
- 1557-3265
- Cited by
- 124
- References
- 2
- Language
- en
- Funders
- NIH/NIDCR (R01DE024601)
- MD Anderson's Cancer Center (P30CA016672)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-0096
- The paper
- Lindemann, A., Patel, A. A., Silver, N. L., Tang, L., Liu, Z., Wang, L., Tanaka, N., Rao, X., Takahashi, H., Maduka, N. K., Zhao, M., Chen, T.-C., Liu, W., Gao, M., Wang, J., Frank, S. J., Hittelman, W. N., Mills, G. B., Myers, J. N., & Osman, A. A. (2019). COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-0096
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.